UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 332

Sortiert nach

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The lancet oncology, 2017-06, Vol.18 (6), p.743-754

2017

Volltextzugriff (PDF)

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Clinical cancer research, 2011-10, Vol.17 (20), p.6437-6447

2011

Volltextzugriff (PDF)

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.689-699

2014

Volltextzugriff (PDF)

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

Pigment cell and melanoma research, 2020-05, Vol.33 (3), p.390-402

2020

Volltextzugriff (PDF)

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

Clinical cancer research, 2009-04, Vol.15 (7), p.2207-2214

2009

Volltextzugriff (PDF)

Evaluation of pre-analytical factors affecting plasma DNA analysis

Scientific reports, 2018-05, Vol.8 (1), p.7375-10, Article 7375

2018

Volltextzugriff (PDF)

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Current drug metabolism, 2012-09, Vol.13 (7), p.901

2012

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

Improved methods for RNAseq-based alternative splicing analysis

Scientific reports, 2021-05, Vol.11 (1), p.10740-10740, Article 10740

2021

Volltextzugriff (PDF)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Breast cancer research : BCR, 2016-03, Vol.18 (1), p.34-34, Article 34

2016

Volltextzugriff (PDF)

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2018-09, Vol.6 (1), p.93-93, Article 93

2018

Volltextzugriff (PDF)

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Journal of clinical oncology, 2004-11, Vol.22 (22), p.4456-4462

2004

Volltextzugriff (PDF)

Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

Journal of clinical oncology, 2012-11, Vol.30 (32), p.4011-4016

2012

Volltextzugriff (PDF)

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5281-5293

2005

Volltextzugriff (PDF)

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

JNCI : Journal of the National Cancer Institute, 2023-02, Vol.115 (2), p.122-124

2023

Volltextzugriff (PDF)

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

Breast cancer research and treatment, 2012-02, Vol.131 (3), p.933-937

2012

Volltextzugriff (PDF)

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

PloS one, 2021-04, Vol.16 (4), p.e0248097-e0248097

2021

Volltextzugriff (PDF)

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Oncotarget, 2017-05, Vol.8 (20), p.32918-32929

2017

Volltextzugriff (PDF)

Differentiation and Definition of Vascular-Targeted Therapies

Clinical cancer research, 2005-01, Vol.11 (2), p.416-420

2005

Volltextzugriff (PDF)

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer

PloS one, 2015-03, Vol.10 (3), p.e0119614

2015

Volltextzugriff (PDF)

Phase I trials as valid therapeutic options for patients with cancer

Nature reviews. Clinical oncology, 2019-12, Vol.16 (12), p.773-778

2019

Volltextzugriff (PDF)

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Clinical cancer research, 2010-07, Vol.16 (14), p.3795-3804

2010

Volltextzugriff (PDF)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004223

2022

Volltextzugriff (PDF)

One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable

The New England journal of medicine, 2020-09, Vol.383 (13), p.1277-1278

2020

Volltextzugriff (PDF)

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

Clinical cancer research, 2015-01, Vol.21 (1), p.60-67

2015

Volltextzugriff (PDF)

1 – 25 von 332

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(316)

Publikationsform

Artikel
(328)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(209)
Life Sciences & Biomedicine
(202)
Humans
(187)
Oncology
(182)
Female
(139)
Middle Aged
(114)
Male
(107)
Aged
(104)
Adult
(97)
Biological And Medical Sciences
(85)
Medical Sciences
(85)
Tumors
(81)
Neoplasms - Drug Therapy
(80)
Pharmacology. Drug Treatments
(71)
Antineoplastic Agents
(69)
Pharmacology & Pharmacy
(65)
Aged, 80 And Over
(49)
Maximum Tolerated Dose
(49)
Chemotherapy
(44)
Antineoplastic Agents - Therapeutic Use
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

Evaluation of pre-analytical factors affecting plasma DNA analysis

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Improved methods for RNAseq-based alternative splicing analysis

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Differentiation and Definition of Vascular-Targeted Therapies

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer

Phase I trials as valid therapeutic options for patients with cancer

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

Suchergebnisse filtern